Cyclic galanin-analogs and uses thereof
Abstract
The invention generally relates to the field of medicine and pharmacology. More particularly, it relates to novel analogs of galanin, and the use thereof in therapy. Provided is a cyclic peptide analog of galanin, wherein the galanin analog comprises a (methyl)Lanthionine bridge and wherein the analog has the general formula “X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17-X18-X19-X20-X21-X22-”, or a truncated variant thereof lacking X1 and/or up to 11 of the C-terminal residues, wherein two residues selected from the group consisting of X3, X4, X6, X7, X10 and X13-X19 together form a Lanthionine bridge of the structure Ala-S-Ala, or a methylLanthionine bridge of the structure Abu-S-Ala or Ala-S-Abu.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . An isolated nucleic acid sequence encoding a peptide selected from the group consisting of
(SEQ ID NO: 58)
GWNTNACGYLLGPHAVGNHR
(SEQ ID NO: 59)
GWNTNACGYLLGPHAVGNH
(SEQ ID NO: 60)
GWNLNAATYLCGPHAVGNHR
(SEQ ID NO: 61)
GWNLNAATYLCGPHAVGNH
(SEQ ID NO: 62)
GWNLNAASYLLCGPHAVGNHR
(SEQ ID NO: 63)
GWNLNAASYLLCGPHAVGNH
(SEQ ID NO: 64)
GWNLNAAGYLLGATAVCNHR
(SEQ ID NO: 65)
GWNLNAAGYLLGATAVCNH
(SEQ ID NO: 66)
GWNLNAAGYLLGASAVC
(SEQ ID NO: 67)
GWNLNAAGYLLGASAVCNHR
(SEQ ID NO: 68)
GWNLNAAGYLLGASAVCNH
(SEQ ID NO: 69)
GWNLNAAGYLLGATAVGCHR
(SEQ ID NO: 70)
GWNLNAAGYLLGASAVGC
(SEQ ID NO: 71)
GWNLNAAGYLLGASAVGCHR
(SEQ ID NO: 72)
GWNLNAAGYLLGASAVGNCR
(SEQ ID NO: 73)
GWNLNAAGYLLGASAVGNC
(SEQ ID NO: 74)
GWNLNAAGYLLGASAVGNHC
(SEQ ID NO: 75)
GWNLNAAGYLLGPHTVGCHR
(SEQ ID NO: 76)
GWNLNAAGYLLGPHSVGC
(SEQ ID NO: 77)
GWNLNAAGYLLGPHATGNCR
(SEQ ID NO: 78)
GWNLNAAGYLLGPHASGNC
(SEQ ID NO: 74)
GWNLNAAGYLLGASAVGNHC
(SEQ ID NO: 79)
QWNLNAAGYLLGATAVCNHR
(SEQ ID NO: 80)
QWNLNAAGYLLGATAVCNH
(SEQ ID NO: 81)
QWNLNAAGYLLGASAVC
(SEQ ID NO: 82)
QWNLNAASYLLC
(SEQ ID NO: 83)
QWNLNAAGYLLGPHTVGCHR
(SEQ ID NO: 84)
GWNLNAAGYLLGTHACG
(SEQ ID NO: 85)
GWNLNAAGYLLGPTAVC
(SEQ ID NO: 86)
GWNLNAAGYLLATHACG
(SEQ ID NO: 87)
GWNLNAAGYLLGATAVC
(SEQ ID NO: 88)
QWNLNAAGYLLATHACG
(SEQ ID NO: 93)
QWNLNAAGYLLGATAVC
(SEQ ID NO: 90)
QWNLNAAGYLLASHACG
(SEQ ID NO: 91)
QWNLNAAGYLLATHACGNHR
(SEQ ID NO: 60)
GWNLNAATYLCGPHAVGNHR
(SEQ ID NO: 92)
QWNLNAAGYLLGPHATGNCR
(SEQ ID NO: 86)
GWNLNAAGYLLATHACG
(SEQ ID NO: 88)
QWNLNAAGYLLATHACG
(SEQ ID NO: 87)
GWNLNAAGYLLGATAVC
(SEQ ID NO: 93)
QWNLNAAGYLLGATAVC
(SEQ ID NO: 94)
GWNVNAAGYLLGATAVCNHR
(SEQ ID NO: 95)
GWNDNAAGYLLGATAVCNHR
(SEQ ID NO: 96)
GWNNNAAGYLLGATAVCNHR
(SEQ ID NO: 97)
GWNLVAAGYLLGATAVCNHR
(SEQ ID NO: 98)
GWNLKAAGYLLGATAVCNHR
(SEQ ID NO: 99)
GWNLDAAGYLLGATAVCNHR
(SEQ ID NO: 100)
GWNLQAAGYLLGATAVCNHR
(SEQ ID NO: 103)
QWNLNAAGYLLGPSAVC
(SEQ ID NO: 104)
QWTLNAASYLLC
(SEQ ID NO: 101)
QWNLNAAGYLLGPTAVC
and
(SEQ ID NO: 102)
QWTLNAATYLLC.
2 . A vector comprising an isolated nucleic acid sequence according to claim 1 , wherein said nucleic acid is genetically fused to a nucleic acid sequence encoding a lanthipeptide-leader sequence.
3 . A food-grade bacterial host cell comprising a vector according to claim 2 .
4 . The food-grade bacterial host cell of claim 3 comprising a L. lactis host cell.
5 . The food-grade bacterial host cell of claim 3 further comprising lanthionine introduction enzymes.
6 . An oral delivery system for production of lanthi-galanins in the gut, said s system comprising the food-grade bacterial host cell of claim 3 .
7 . A pharmaceutical composition comprising viable host cells according to claim 3 and a pharmaceutically acceptable carrier, diluent or vehicle.
8 . The pharmaceutical composition of claim 7 formulated for oral administration.
9 . A method of treating or alleviating symptoms associated with inflammatory bowel disease, said method comprising administering to a subject in need thereof a pharmaceutical composition according to claim 7 .
10 . The method of claim 9 wherein the inflammatory bowel disease is Crohn's disease or ulcerative colitis (UC).Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.